Linde India Ltd. announces an acquisition
TL;DR
What are the trailing twelve-month (TTM) revenue and EBITDA figures for Airtech Cryogenic Gases, and what is the implied EV/EBITDA valuation multiple based on the INR 111.20 crore acquisition price?
Airtech Cryogenic Gases’ TTM revenue and EBITDA cannot be confirmed from the acquisition disclosure. The filing reports turnover of ₹28.9995 Cr for nine months of operation and an estimated cash acquisition price of ₹111.20 Cr, subject to closing adjustments [1].
- TTM revenue: Not confirmed. The closest reported figure is ₹28.9995 Cr for nine months, not a TTM figure [1].
- TTM EBITDA: Not confirmed; no EBITDA figure is reported in the cited acquisition details.
- Implied EV/EBITDA: Not computable without TTM EBITDA. Also, the ₹111.20 Cr consideration is an estimated cash acquisition cost, so treating it as enterprise value would itself be an approximation [1].
For reference, dividing the acquisition price by the reported nine-month turnover gives a 3.83x price-to-nine-month-revenue ratio—not an EV/EBITDA multiple.
Does the acquisition of Airtech Cryogenic Gases provide Linde India with incremental manufacturing capacity or specific geographic market access that was previously underserved, and what is the expected timeline for the completion of the share transfer?
The transaction appears to add access to an existing manufacturing asset, but the filing does not establish a previously underserved geographic market.
- Incremental capacity: Airtech operates an Air Separation Unit at Dholka, Gujarat and manufactures, sells and distributes industrial and medical cryogenic gases. Acquiring 100% of Airtech would therefore give Linde India an additional production footprint in Gujarat. However, the filing does not quantify the ASU’s capacity, utilization or the amount of capacity incremental to Linde’s existing network. [2]
- Geographic access: Dholka provides a more specific Gujarat-based operating presence, but Linde India has not stated that the region was previously underserved, nor identified a market-access gap, new customer cluster or exclusive territory being acquired. The disclosed rationale is broader—strengthening the core business, scale and growth. [1]
- Completion timeline: The share purchase agreement was executed on 13 November 2026. The indicative completion period is within eight weeks, which implies around 8 January 2027, subject to fulfilment of conditions precedent and closing adjustments. [3] [1]
The transaction is therefore best characterized as an asset-backed expansion of Linde’s Gujarat manufacturing footprint, rather than a clearly documented entry into a previously underserved geography. The acquisition disclosure states that no governmental or regulatory approvals are required, although other transaction conditions still apply. [1]
How does the INR 111.20 crore cash outflow for this acquisition compare to Linde India’s current cash and cash equivalents and its average annual capital expenditure (Capex) over the last three fiscal years?
The ₹111.20 Cr cash consideration is sizeable relative to Linde India’s liquidity but modest against its recent investment run-rate:
- Versus cash: Linde India reported ₹204.58 Cr of consolidated cash and equivalents at Q2 FY27 [4]. The acquisition consideration therefore equals 54.4% of reported cash; cash was 1.84x the transaction value. If funded entirely from that balance, the mechanical residual would be about ₹93.38 Cr, before other cash movements.
- Versus capex: Reported capex was ₹571.68 Cr in FY24, ₹1,330.50 Cr in FY25, and ₹766.22 Cr in FY26 [5] [6] [7]. The three-year average is ₹889.47 Cr, making the acquisition consideration equivalent to 12.5% of average annual capex.
Interpretation: The outflow is large relative to quarter-end cash, so it could materially reduce reported liquidity if paid directly from cash. However, it is only about one-eighth of the recent average annual capex, suggesting the transaction is not large relative to Linde India’s broader capital-investment scale.
Caveat: The cash balance is as of 30 September 2026, while the acquisition announcement dated 13 November 2026 stated that completion was expected within eight weeks of signing; therefore, ₹204.58 Cr is a reference-point balance, not a pro forma post-acquisition cash figure [8].
Sources
- [1]Linde India to Acquire 100% Stake in Airtech Cryogenic Gases for INR 111.20 Crore — 2026-11-13T20:12:25.350000, p.2
- [2]Linde India to Acquire 100% Stake in Airtech Cryogenic Gases for INR 111.20 Crore — 2026-11-13T20:12:25.350000, p.3
- [3]Linde India to Acquire 100% Stake in Airtech Cryogenic Gases for INR 111.20 Crore — 2026-11-13T20:12:25.350000, p.1
- [4]Cash and Equivalents
- [5]TTM Capex
- [6]TTM Capex
- [7]TTM Capex
- [8]Linde India Acquisition Worth ₹111.2 Cr | LINDEINDIA | 13 Nov 2026 — Alfafinder, 2026-11-13T00:00:00
Keep digging